Boehringer Ingelheim

Boehringer Ingelheim Leadership Changes

Shashank Deshpande, member of the Board of Managing Directors, has been appointed Chairman of the Board of Managing Directors.

Boehringer Ingelheim Opens New R&D Center in Basel

NBE Therapeutics (NBE), a wholly owned subsidiary of  Boehringer Ingelheim, officially opened its new ADC R&D facility in Basel.

Boehringer Ingelheim Expands Cancer Research at Vienna Site

On Sep. 25, German biopharma company Boehringer Ingelheim opened its new 11,000 sqm Angelika Amon Research Building at its site in Vienna, Austria. According to Boehringer Ingelheim, the investment of around €60 million is further proof of the company's commitment to cancer research.

Quantro and Boehringer Ingelheim Hit Milestone in Cancer Treatment Development

Quantro Therapeutics, which focuses on transcription factors targeting cancer treatments, announced that it has reached a key milestone in its joint R&D program with Boehringer Ingelheim.

Sustainability from the Beginning

The idea that statistics can address urgent sustainability concerns at the lab bench was central to presentations at the recent JMP Discovery Summit Europe in Manchester, UK.

Boehringer to Expand Greek Production Site for New Medicines

German drugmaker Boehringer Ingelheim is investing €120 million in an upgrade and expansion of its facility in Koropi, Greece, that will increase the company's capacity to produce existing and new medicines. Main disease areas, Boehringer said, include cardio-renal-metabolic (CRM) diseases, mental health, and pulmonary fibrosis.

Gingko Enters Dyes and Drugs Partnerships

US biology company Ginkgo Bioworks has announced two separate partnerships, one on natural colors and dyes with Octarine Bio and the other on novel therapeutic molecules with drugmaker Boehringer Ingelheim.

Boehringer Ingelheim, Evotec and BioMérieux Link on AMR

German biopharma Boehringer Ingelheim, compatriot CDMO Evotec and French diagnostics firm BioMérieux have formed a joint venture to develop a new approach to fight the rise of antibiotic-resistant infections.

Ramping Up Biomanufacturing Capacity

Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an active area of investment for CDMOs/CMOS. Some of the major investments by the larger CMDOs/CMOs are outlined in this article.

BearingPoint Client Success Story: Boehringer Ingelheim increases Data Accuracy by leveraging Robotic Process Automation

Storage conditions play a vital role in the entire supply chain of pharmaceutical products and must comply with strict regulations. From manufacturers to patients, storage conditions are essential for the quality, safety, and efficacy of medications.

Boehringer Inaugurates BioPharma Plant in Austria

Boehringer Ingelheim has inaugurated its Large Scale Cell Culture (LSCC) biopharmaceutical plant at Vienna, Austria. Built over a period of six years at a cost of more than €700 million, the German drugmaker said this is the single largest investment in its history.

The Transition to Digitalization in the Pharmaceutical Industry

ISPE and its members are developing the roadmap to introduce Industry 4.0, also called the Smart Factory, at the pharmaceutical industry as Pharma 4.0 – an operating model that is interconnected, meaning that the digital tools allow for a fully connected network to enable direct communication between all levels in an organization.

Expert Statement: Viola Meisterling, Boehringer Ingelheim

ISPE and its members are developing the roadmap to introduce Industry 4.0, also called the Smart Factory, at the pharmaceutical industry as Pharma 4.0 – an operating model that is interconnected, meaning that the digital tools allow for a fully connected network to enable direct communication between all levels in an organization.

Nanoform and Boehringer in Master Services Pact

Finnish nanoparticle medicine specialist Nanoform and German drugmaker Boehringer Ingelheim have agreed to collaborate on proof-of-concept studies related to Nanoform’s proprietary Controlled Expansion of Supercritical Solution (CESS) platform.

Boehringer Ingelheim and Enara Bio in Cancer Pact

German drugmaker Boehringer Ingelheim and UK biotech Enara Bio have agreed to collaborate on the research and development of novel targeted cancer immunotherapies, leveraging Enara Bio’s proprietary Dark Antigen Platform Technology (EDAPT).

Böhringer to Settle More Pradaxa Cases

German privately owned drugmaker Böhringer Ingelheim has reached an agreement in principle to settle nearly 3,000 US lawsuits alleging that its Pradaxa (dabigatran etexilate) anticoagulant drug caused undisclosed bleeding risks. Most of the lawsuits have been filed in the judicial district of Hartford, Connecticut.

The Impact of Covid-19 on the Pharmaceutical Industry

Andrew Badrot, CEO of C2 Pharma and a close observer of pharma industry trends, analyzes the current situation and how this pandemic may kick of changes in the pharma market.

Technology and Innovation in the Pharmaceutical Industry

Injecting Growth and Innovation

Boehringer to Reshuffle Some Management Jobs

Live-Broadcasting of Bioprocesses

Boehringer Buys AMAL Therapeutics

Boehringer and Gubra Link on Obesity

Boehringer Ingelheim Expanding in Mexico

Advocacy Group Sues FDA Over Dopamine Warnings

Japan’s AGC to buy Malgrat Pharma

Boehringer Expands Biopharmaceuticals in US

Boehringer Ingelheim Buys ViraTherapeutics

Boehringer plans Solids Launch Unit

Boehringer Refocuses AD drug on Schizophrenia

Boehringer Wins Europe’s First Biosimilar Approval

Boehringer Ingelheim and Dicerna in NASH Pact

The Chemical Footprint in Pharma

Sanofi to Sell Five OTC Products to Ipsen

Sanofi and Boehringer Complete Swap